Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 8, 1127-1130 doi:10.3324/haematol.11288
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carlotti, E.
Right arrow Articles by Rambaldi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carlotti, E.
Right arrow Articles by Rambaldi, A.

Malignant Lymphomas

Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab

Emanuela Carlotti, Giuseppe A. Palumbo, Elena Oldani, Daniele Tibullo, Silvia Salmoiraghi, Andrea Rossi, Josee Golay, Alessandro Pulsoni, Robin Foà, Alessandro Rambaldi

From the Divisione di Ematologia, Ospedali Riuniti Bergamo (EC, EO, SS, AR, JG, AR); CRUK Medical Oncology Laboratory, Barts and the London, Queen Mary School of Medicine and Dentistry, London, United Kingdom (EC); Dipartimento di Ematologia, Scienze Biomediche, Universita’, Catania (GAP, DT); Dipartimento di Biotecnologie Cellulari ed Ematologia, Università ‘La Sapienza’, Rome, Italy (AP, RF)

Correspondence: Alessandro Rambaldi, M.D., USC Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. E-mail: arambaldi{at}ospedaliriuniti.bergamo.it

We analyzed Fc{gamma}RIIIA-158V/F and Fc{gamma}RIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between Fc{gamma}RIIIA-158VV/VF and Fc{gamma}RIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

Key words: Fc{gamma}R polymorphisms, follicular lymphoma, BCL2/IgH rearrangements.




This article has been cited by other articles:


Home page
 haematolHome page
N. M. Pennell, T. Bhanji, L. Zhang, A. Seth, C. A. Sawka, and N. L. Berinstein
Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma
Haematologica, August 1, 2008; 93(8): 1265 - 1267.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.